1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
A Product and Pipeline Analysis of the Antibacterial Drugs Market : Regulatory Approaches to Combat Microbial Resistance and Stimulate Antibiotics R&D

A Product and Pipeline Analysis of the Antibacterial Drugs Market : Regulatory Approaches to Combat Microbial Resistance and Stimulate Antibiotics R&D

  • January 2015
  • 122 pages
  • ID: 2649483
  • Format: PDF
  • By Frost & Sullivan

Summary

Table of Contents

Key Findings

•2014 has turned out to be a flagship year in the history of antibacterial drugs development.
oThree new systemic antibacterial drugs gained Food and Drugs Administration (FDA) approval for acute bacterial skin and skin structure infection in 2014, including Dalvance (Durata Therapeutics), Orbactive (The Medicines Company), and Sivextro (Cubist Pharmaceuticals).
oNew Drug Applications (NDA) were submitted for two combination bacterial therapies for complicated Urinary Tract Infection (UTI) and complicated intra-abdominal infection indications in 2014.
oOnly two new systemic antibacterial agents were approved for use in humans by the US FDA from 2008–2012, while sixteen of them were approved from 1983–1987, including Ceftolozane/Tazobactam (Cubist Pharmaceuticals) and Ceftazidime/Avibactam (AstraZeneca/Forest Laboratories).
oIt is alarming to note that no new classes of antibacterial drugs have been approved for the treatment of Gram-negative Bacilli (GNB) in the last 40 years, leaving fluoroquinolones as the last new class of antibacterial drugs to treat GNB.
oDrug-resistant bacteria, or superbugs, pose a serious threat to human health.
oAccording to the Centre for Disease Control and Prevention (CDC), x million Americans acquire serious infections caused by antibiotic-resistant bacteria every year, of which x die.
oDeveloping new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less attractive segment for investment by pharmaceutical companies.
oSeveral new initiatives and measures have been adopted by agencies such as the FDA and the Infectious Diseases Society of America (IDSA) to spur the development of novel antibacterial drugs and help lure companies back into antibacterial research and development (R&D).

•Currently, there are x new antibacterial drugs in the development stage that could potentially address many, but not all, resistant bacteria, as per the findings of the PEW Charitable Trusts.
oOf the x drugs in the pipeline, x are in phase x clinical trials, x in phase 2, x in phase 3, and x have submitted NDAs.
oThree of the seven antibacterial drugs in phase 3, as well as the two drugs submitted for FDA review, are known to have the potential to address the single most pressing unmet need—infections caused by GNB.
oAt least of the antibacterial drugs in the pipeline are designated as “qualified infectious disease products (QIDP)” which means they are being studied for serious or life-threatening infections and are entitled to receive benefits provided under the Generating Antibiotic Incentives Now (GAIN) Act of 2012.
oAt least two antibacterial drugs in the early stages of development represent an entirely new class of drugs by sidestepping the resistance of some bacteria to available antibacterial drugs, while the others target the same existing components using new chemical compounds; these include FabI inhibitors and Defensin-mimetics.

•Given the high probability of product failure and R&D costs, big pharma companies have exited the antibacterial drugs market in the past. For example, Pfizer that was once a leader in the antibiotics R&D space closed its antibacterial research facility in Connecticut in 2011.
oOf the x or so companies developing antibacterial drugs, only x are big pharma companies, including GlaxoSmithKline, AstraZeneca, and Merck & Co.
oRoche recently made a big come-back into the antibiotics field after having exited this market in 1999. The company has entered into strategic license agreement partnerships with three small biotech companies—Pylor, Discuva Ltd., and Spero Therapeutics.
oSanofi-aventis, Eli Lilly, and Bristol-Myers Squibb (BMS) are among the notable big pharma companies that have exited antibiotics R&D since the 1990s.
oNearly x % of the products currently in the pipeline are being developed by smaller pharma or biotech companies, of which half of them are pre-revenue companies, which means they do not have any commercialized products in the market.

•Research hospitals and universities are also known to make huge contributions toward the development of novel antibiotics for the treatment of drug-resistant superbugs.
oResearchers from the University of British Columbia have recently discovered a peptide to combat infections caused by Gram-positive bacteria by breaking up biofilms or clusters of bacteria impossible to be treated with antibiotics.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Pyelonephritis - Pipeline Review, H2 2019

Pyelonephritis - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Pyelonephritis - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Pyelonephritis - Pipeline Review, H2 2019, provides an overview of the Pyelonephritis (Infectious ...

Immunosuppressant Therapeutic Drug Monitoring - Medical Devices Pipeline Assessment, 2019

Immunosuppressant Therapeutic Drug Monitoring - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Immunosuppressant Therapeutic Drug Monitoring - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Immunosuppressant Therapeutic Drug Monitoring - Medical Devices Pipeline ...

Global Antibiotics Partnering Terms and Agreements 2014 to 2019: Deal trends, players and financials

Global Antibiotics Partnering Terms and Agreements 2014 to 2019: Deal trends, players and financials

  • $ 2995
  • November 2019

The Global Antibiotics Partnering Terms and Agreements 2014 to 2019 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare ...


ref:plp2015

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on